Hepatitis B Virus News and Research

RSS

Warning over sirolimus in HCV-positive liver transplantation

Sirolimus, whether given at the time of liver transplantation or after, is associated with poorer outcomes in patients with hepatitis C virus infection compared with those who do not take the immunosuppressant, shows a US study.

10 Sep 2012

Children and young patients with chronic HBV infection do have a protective immune response

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

7 Sep 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

CDC: Baby boomers should be tested for Hep C

Americans born between 1945 and 1965 are at particularly high risk for Hepatitis C and should be tested, according to new recommendations from the Centers for Disease Control and Prevention.

18 Aug 2012

First Edition: August 17, 2012

Now on Kaiser Health News' blog, Jenny Gold reports on a new survey about accountable care organizations: "Few hospitals interested in becoming accountable care organizations are ready to take on financial risk, according to a survey released Friday from The Commonwealth Fund."

17 Aug 2012

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

Researchers have discovered molecular and protein signatures that predict rapid onset of liver damage in hepatitis C patients following a liver transplant. The markers appeared soon after transplant and well before clinical evidence of liver damage.

17 Aug 2012

CDC recommends hepatitis C screening for all patients born from 1945-1965

Without other risk factors, all Americans born between 1945 and 1965 should have a one-time screening for the hepatitis C virus (HCV) according to new recommendations being published early online today in Annals of Internal Medicine, the flagship journal of the American College of Physicians. The Centers for Disease Control and Prevention (CDC) also recommends that all persons identified with HCV should receive a brief alcohol screening and intervention and be referred to appropriate care and treatment services for HCV and related conditions.

17 Aug 2012

TAT-ARC fusion protein helps treat acute liver failure

Acute liver failure is a life-threatening disease, characterized by a sudden, massive death of liver cells. Unfortunately, few treatment options exist, especially for advanced-stage liver failure. As a last resort a liver transplant may be the only remaining option.

3 Aug 2012

Two new targets could enhance the body's defenses against West Nile and hepatitis C

Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection warning system inside living cells.

31 Jul 2012

EASL calls on the UN to take action to fight against viral hepatitis infection

Marking World Hepatitis Day, the European Association for the Study of the Liver (EASL) calls on the different organizations which make up the United Nations systems to take action to fight against Viral Hepatitis (Hepatitis B and C), a potentially fatal infection of the liver which affects 500 million people.

30 Jul 2012

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Scientists at the National Institutes of Health have identified several factors in people infected with the hepatitis C virus that may predict whether the unusually rapid progression of disease from initial infection to severe liver conditions, such as cirrhosis, will occur. Knowing whether a patient's condition is likely to deteriorate quickly could help physicians decide on the best course of treatment.

27 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Since its discovery in 1989, hepatitis C virus (HCV) has been recognized as a major cause of chronic liver disease worldwide. The most recent WHO estimate of the prevalence of HCV infection is 2%, representing . about 150 million people. Every year, 3–4 million new people are infected with the hepatitis C virus, of those, approximately 60–80% develop chronic hepatitis, and 30% of them progress to cirrhosis and to end-stage liver disease.

26 Jul 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

Herbal therapy no alternative in HCV infection

The commonly used herbal remedy, silymarin, offers no benefit to patients with treatment-resistant hepatitis C virus infection, a study shows.

23 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

HCV infections can lead to increased mortality from liver disease or variety of other causes

In a long-term study of people infected with the hepatitis C virus (HCV), researchers found increased deaths from both liver-related and non-liver related diseases in patients with active infections who had not cleared their infection.

19 Jul 2012

Hepatitis B Virus News and Research

Warning over sirolimus in HCV-positive liver transplantation

Children and young patients with chronic HBV infection do have a protective immune response

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

FDA approves Gilead’s Stribild to treat HIV-1 infection

CDC: Baby boomers should be tested for Hep C

First Edition: August 17, 2012

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

CDC recommends hepatitis C screening for all patients born from 1945-1965

TAT-ARC fusion protein helps treat acute liver failure

Two new targets could enhance the body's defenses against West Nile and hepatitis C

EASL calls on the UN to take action to fight against viral hepatitis infection

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Herbal therapy no alternative in HCV infection

Silymarin does not offer significant improvements for patients with HCV

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

HCV infections can lead to increased mortality from liver disease or variety of other causes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News